

**Request for information under the Freedom of Information Act – 2021.934  
Released – 26 August 2021**

Thank you for your email received 23 August 2021 requesting information regarding the treatment of schizophrenia.

Please find detailed below a summary of your request, together with our response.

**Summary of your original request:**

**Q1. In the past 6 months, how many patients has your trust treated [for any condition] with the following drugs:**

- **Aripiprazole long-acting injectable (Abilify Maintena)**
- **Olanzapine pamoate (Zypadhera)**
- **Paliperidone palmitate, once monthly (Xeplion)**
- **Paliperidone palmitate, three monthly (Trevicta)**
- **Risperidone long-acting injectable (Risperdal Consta)**
- **Flupentixol decanoate (Depixol)**
- **Fluphenazine decanoate (Modecate)**
- **Haloperidol decanoate (Haldol Decanoate)**
- **Pipotiazine palmitate (Piportil)**
- **Zuclopenthixol decanoate (Clopixol)**

**Q2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)**

**Q3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:**

- **Aripiprazole long-acting injectable (Abilify Maintena)**
- **Olanzapine pamoate (Zypadhera)**
- **Paliperidone palmitate, once monthly (Xeplion)**
- **Paliperidone palmitate, three monthly (Trevicta)**
- **Risperidone long-acting injectable (Risperdal Consta)**
- **Flupentixol decanoate (Depixol)**
- **Fluphenazine decanoate (Modecate)**
- **Haloperidol decanoate (Haldol Decanoate)**
- **Pipotiazine palmitate (Piportil)**
- **Zuclopenthixol decanoate (Clopixol)**

The Kent Community Health NHS Foundation Trust does not provide treatment for schizophrenia; therefore we do not hold any information pertinent to your request.

Chairman John Goulston Chief Executive Paul Bentley

Trust HQ The Oast, Unit D, Hermitage Court, Hermitage Lane, Barming, near Maidstone, Kent ME16 9NT